Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 13/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.40 |
| ▸ | ADA | P00813 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22912613 | 0.86 | SLC29A1 (0.39) | ADKSLC29A1ADA | |
| SCHEMBL20917264 | 0.86 | SLC29A1 (0.39) | ADKSLC29A1ADA | |
| SCHEMBL3768787 | 0.79 | ADK (0.61) | ADKSLC29A1 | |
| SCHEMBL13068771 | 0.79 | ADK (0.61) | ADKSLC29A1 | |
| SCHEMBL20419264 | 0.79 | ADK (0.61) | ADKSLC29A1 | |
| SCHEMBL2578051 | 0.77 | SLC29A1 (0.47) | SLC29A1ADA | |
| SCHEMBL12174029 | 0.77 | SLC29A1 (0.47) | SLC29A1ADA | |
| SCHEMBL3772364 | 0.77 | ADK (0.46) | ADKSLC29A1 | |
| SCHEMBL16316525 | 0.77 | ADK (0.46) | ADKSLC29A1 | |
| SCHEMBL20916985 | 0.76 | PRMT5 (0.45) | ADKSLC29A1ADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072628-B2 | Nucleoside analogues for the treatment of parasitic infections | UNIVERSITEIT GENT (BE) | 2021-07-27 | — | — | US | disclosed |
| US-20210024566-A1 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS | UNIVERSITEIT GENT (BE) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072628-B2 | Nucleoside analogues for the treatment of parasitic infections | PNP, NUDT1, SAMHD1 | ADK 109/4885SLC29A1 11/4885ADA 25/4885 |
| US-20210024566-A1 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS | PNP, NUDT1, SAMHD1 | ADK 109/4885SLC29A1 11/4885ADA 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.